Large conducting potassium channel reconstituted from airway smooth muscle.
Microsomal fractions were prepared from canine and bovine airway smooth muscle (ASM) by differential and gradient centrifugations. Surface membrane vesicles were characterized by binding assays and incorporated into planar lipid bilayers. Single-channel activities were recorded in symmetric or asymmetric K+ buffer systems and studied under voltage and Ca2+ clamp conditions. A large-conductance K(+)-selective channel (greater than 220 pS in 150 mM K+) displaying a high Ca2+, low Ba2+, and charybdotoxin (CTX) sensitivity was identified. Time analysis of single-channel recordings revealed a complex kinetic behavior compatible with the previous schemes proposed for Ca(2+)-activated K+ channels in a variety of biological surface membranes. We now report that the open probability of the channel at low Ca2+ concentration is enhanced on in vitro phosphorylation, which is mediated via an adenosine 3',5'-cyclic monophosphate-dependent protein kinase. In addition to this characterization at the molecular level, a second series of pharmacological experiments were designed to assess the putative role of this channel in ASM strips. Our results show that 50 nM CTX, a specific inhibitor of the large conducting Ca(2+)-dependent K+ channel, prevents norepinephrine transient relaxation on carbamylcholine-precontracted ASM strips. It was also shown that CTX reversed the steady-state relaxation induced by vasoactive intestinal peptide and partially antagonized further relaxation induced by cumulative doses of this potent bronchodilatator. Thus it is proposed that the Ca(2+)-activated K+ channels have a physiological role because they are indirectly activated on stimulation of various membrane receptors via intracellular mechanisms.
Department of Physiology, Faculty of Medicine, University of Sherbrooke, Quebec, Canada.
D
D
Savaria
C
C
Lanoue
A
A
Cadieux
E
E
Rousseau
D000818:Animals; D001464:Barium / Q000494:pharmacology; D001920:Bradykinin / Q000378:metabolism; D002118:Calcium / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D002417:Cattle; D002458:Cell Fractionation; D018999:Charybdotoxin; D000242:Cyclic AMP / Q000494:pharmacology; D004285:Dogs; D004553:Electric Conductivity; D066298:In Vitro Techniques; D008051:Lipid Bilayers; D008861:Microsomes / Q000187:drug effects / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology*; D011494:Protein Kinases / Q000378:metabolism / Q000494:pharmacology; D018002:Receptors, Bradykinin; D011950:Receptors, Cholinergic / Q000378:metabolism; D017981:Receptors, Neurotransmitter / Q000378:metabolism; D012433:Ryanodine / Q000378:metabolism; D019837:Ryanodine Receptor Calcium Release Channel; D012604:Scorpion Venoms / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects / Q000502:physiology*
D008051:Lipid Bilayers; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D015221:Potassium Channels; D018002:Receptors, Bradykinin; D011950:Receptors, Cholinergic; D017981:Receptors, Neurotransmitter; D019837:Ryanodine Receptor Calcium Release Channel; D012604:Scorpion Venoms; D018999:Charybdotoxin; D012433:Ryanodine; D001464:Barium; D002217:Carbachol; D000242:Cyclic AMP; D011494:Protein Kinases; D001920:Bradykinin; D002118:Calcium; D009638:Norepinephrine